A potency assay for Western equine encephalomyelitis vaccine was developed which utilized mice as the test animal instead of guinea pigs or hamsters. By immunizing several groups of mice with dilutions of the vaccine and challenging them intracerebrally with virulent virus, it was possible to determine mathematically a dose of vaccine capable of protecting 50% of the animals (ED50). When log dilutions of virulent virus were used to challenge mice which were immunized with dilutions of the vaccine, there was no difference among the ED50 values for the dilutions of challenge virus. In a direct comparison of ED50 values determined from the immunization of mice and those determined from the immunization of guinea pigs, there were no differences in the rankings of the vaccines.
guinea pigs for equine encephalomyelitis vaccines using a series of two 0.1-ml intradermal doses of vaccine. A vaccine was considered satisfactory if 80 to 100% of the animals were protected against an intracerebral (ic) challenge of 100 to 1,000 median lethal doses (LD50).
For the potency testing of animal vaccines, the U.S. Department of Agriculture (7) has modified the vaccinations to two 0.5-ml subcutaneous (SQ) doses; for acceptable potency, 80% of the vaccinated guinea pigs must survive a 0.1-ml ic challenge which will kill at least 80% of the nonvaccinated controls.
In our laboratory the test has been further modified by vaccinating guinea pigs SQ with two 0.5-ml doses of serial fivefold dilutions of the vaccine, (i.e., 1:5, 1:25, and 1:125) and then challenging them with a constant level of virulent virus (6) . Cole and McKinney (2) utilized hamsters as the test animal in an assay which was also based on immunizing with dilutions of vaccine. The results in both of these cases are reported as milliliters of undiluted vaccine effective in protecting 50% of the challenged animals (ED80) and are used to compare the potencies of different lots of vaccine.
The first two tests (1, 2) 
MATERIALS AND METHODS
Vaccines and challenge virus. The method of cell culture vaccine production and the source of the challenge virus have been previously described (6) .
Potency tests. The assay methods utilizing guinea pigs have been previously described (6) .
For the potency assays in mice, CD-1 strain, 3-week-old white mice (Charles River Mouse Farms, Wilmington, Mass.) were divided into groups of 16, and each group was vaccinated intraperitoneally (ip) with serial fivefold dilutions of the vaccine (1: 1, 1: 5, 1:25, and 1:125) on days 0 and 3. This conforms to the Public Health Service requirements for Japanese encephalitis vaccine (3) . A fresh vial of freeze-dried vaccine from the same lot was reconstituted and diluted for the second dose. The mice were challenged (Table  4) . Although, the guinea pigs gave lower ED50 values than did the mice, the guinea pig ED50 values also had greater confidence limits than the mouse values. This may be a reflection of the smaller numbers of animals used per dilution in the guinea pig test (10 as compared to 16 in the mouse assay).
By comparison of the confidence limits, vaccine C was less potent than vaccine D in both mice and guinea pigs, whereas vaccines E, F, and G could not be differentiated from each other. However, vaccines E, F, and G could be differentiated from D. Therefore, the ranking of the vaccines in both mouse and guinea pig assays was identical: C, then D, and then a group composed of E, F, and G.
DISCUSSION
The final mouse potency assay that was developed consisted of ip vaccination with 0.2-ml doses of serial fivefold dilutions of vaccine on days 0 and 3 and subsequent ic challenge containing 100 to 1,000 LD50 of virulent virus on day 14. The assays were terminated and statistically evaluated at 14 days postchallenge. Dilutions of vaccine were chosen to include 0 and 100% mortality after challenge with virulent virus. Obviously, higher dilutions would have to be used if a more potent vaccine were being assayed.
The similarity of the ED5,0 values when the vaccinated mice were challenged with log10 dilutions of virulent virus was comparable to that found with formalinized Rift Valley Fever vaccine (1). In both cases, the critical factor was the amount of antigen in the immunizing dose rather than the LD50 of virulent virus in the challenge dose. This enables valid potency and stability comparisons to be made even if the challenge dose varies greatly. When the same vaccines were compared in mice and guinea pigs by using parallel assays, there were no differences in the rankings, which indicates that comparable data could be derived from either assay.
The mouse potency assay for WEE vaccine is advantageous in several ways. The assay is completed in 28 days, which is 7 days less than the guinea pig or hamster assays. In addition, larger numbers of mice can be housed in a given area, thus increasing the number of assays that may be conducted and the number of mice that can be used per assay. This would increase the statistical validity of the assay. Finally, animal costs are reduced by 85% as compared to the other assay systems.
